Skip to main content

Speakers

A number of UK and International speakers with research and clinical backgrounds have been invited to speak about their world-leading research at the cutting edge of research and clinical science.

 

Confirmed Plenary Speakers

Dr John McGhee, University of New South Wales

A practicing 3D CGI artist, researcher and senior lecturer, McGhee has background in design and 3D computer arts research. His visual practice explores arts-led modes of visualising complex scientific and biomedical data using the 3D CGI techniques used in the visual effects and animation industries. His academic research builds on this theme - which was the basis for his doctoral thesis - and has since resulted in a variety of collaborative projects across the visual arts and sciences. Examples include projects in clinical imaging, microscopy, asthma care and infection control, with a view to improved models of working between artists, patients, the public and healthcare professionals.

 

Dr Angus Johnston, Monash University

Dr Angus Johnston is an ARC Future Fellow whose work focuses on developing better ways to deliver drugs, making them more therapeutically active and limiting side effects. He has extensive knowledge and expertise in nanomaterials assembly, material characterisation, cellular interactions and advanced imaging techniques. His group is interested in understanding how nanoengineered materials interact with biological systems. This work involves developing molecular sensors to determine the internalisation, trafficking and local environment that nanoparticles are exposed to in living cells. With a better understudying of how these material interact with cells, we can engineer smarter materials for improved drug and vaccine delivery.

 

Confirmed Invited Speakers

Dr Olu Adesanya, University Hospital Coventry and Warwickshire

Olu Adesanya graduated from University of Benin in 1995. He then underwent general medicine training in the UK and subsequently completed his radiology and nuclear medicine (including PET-CT) training in Birmingham and Zurich. He took up the post of Consultant in Radiology at the University Hospitals Coventry and Warwickshire in May 2007. Hi clinical interests include head and neck imaging including CT, MRI, fine needle aspiration of thyroid and other head and neck lumps; skull base pathologies; head & neck tumours; radionuclide imaging with PET-CT and SPECT-CT. Amongst other interests, Olu is closely involved in the PET-NECK study research, a multi-centre randomised phase III trial, comparing PET-CT guided watch and wait policy, versus planned neck dissection for the management of locally advanced (N2/N3) nodal metastases in patients with head and neck squamous cancer.

 

Prof. Charles Hutchinson, University Hospital Coventry and Warwickshire and University of Warwick, UK

Prof. Charles Hutchinson is a Consultant Radiologist at University Hospital Coventry and Warwickshire (UHCW) and is also Professor of Clinial Imaging at the Warwick Medical School, University of Warwick. His research was initially in the use of 3D MR for radiotherapy planning in the prostate. Much of his recent research has been in Osteoarthritis (OA) and in image modelling, though he has maintained an interest in Onocolgy imaging. Currently he is involved in an OA study with Manchester (Dr Callaghan, Prof O'Neill and Prof Cootes) and Boston (Prof Felson); a study in modelling wrist motion with Dr Graham in Manchester; in imaging in Scleroderma with Prof Herrick in Manchester; and modelling the bowel motion in Sclerosing Peritonitis (Dr Summers) in Manchester. In the University of Warwick, he is looking at the changes seen on CT in Interstitial fibrosis, the patterns of change seen in prothesis loosening on PET-CT imaging and characterising MR in Brown Fat imaging and in Myositis. He is currently leading the set up of fMRI imaging facilities with UHCW.

 

Prof. John Marshall, Barts Cancer Institute, Queen Mary University London

John Marshall's career in research science began in the Tissue-Interactions Laboratory of Imperial Cancer Research Fund (now Cancer Research UK) in January 1983. He then moved within ICRF to study Invasion and Metastasis with Ian Hart in 1984, where he spent 6 years developing photosensitisers for laser activated tumour therapy. His PhD studies took him towards an investigation of integrins in melanoma. In 1998, he moved from melanoma to carcinoma; his team worked on the epithelial-specific αvβ6 as a pro-invasive integrin, using it as a paradigm for the study of integrin-dependent pro-invasive biology. His group has developed αvβ6-specific targeting agents some of which are being developed for clinical trials. In recent years, he has worked closed with DebRA, the Breast Cancer Campaign (BCC) and the Pancreatic Cancer Research Fund (PCRF).

Title of presentation: Development of peptides for imaging integrin alpha-v beta-6 in cancer

 

Dr Nicola Rogers, Durham University

Nicola Rogers is a Research Associate in the team led by Prof. David Parker at Durham University. Research in the Parker Group with wide ranging, with one research strand involving the synthesis and characterisation of functional magnetic resonance probes, developing responsive and targeted paramagnetic contrast agents (e.g. for cancer imaging), using ParaShift Magnetic Resonance Imaging and Spectroscopy.

 

Dr Kristofer Thurecht, University of Queensland, Australia

Dr Thurecht’s research focusses on the development of polymer and nanoparticle-based devices for nanomedicine. For polymers to be truly effective in nanomedicine, they must incorporate new therapies while maintaining their physical and chemical integrity. This can only be achieved by developing a strong understanding of the fundamental properties of the nanomaterial-delivery system, in addition to identifying and successfully delivering new therapies. Central to the development of these future therapeutic platforms, is the field of theranostics, where molecular imaging plays a key role in understanding the dynamics of polymeric nanomedicines. Dr Thurecht’s team works across the boundaries of chemistry and materials, biology and imaging science to probe how nanomaterial properties affect their function in living animals.

 

Prof. Andrew Whittaker, Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia

Andrew Whittaker is a physical chemist with an international reputation in three fields, namely 1) magnetic resonance of materials, 2) polymeric biomaterials and 3) polymers for photolithography. In the field of NMR and MRI of materials he has performed important research on the structure of inorganic and organic (mainly polymeric) materials; in the field of biomaterials he has made advances to our understanding of transport in biomaterials, and the design of novel imaging agents; in the field of lithography his work continues to inform the International Technology Roadmap for Semiconductors. Over the past decade Whittaker and his team have introduced several new concepts in fluorinated MR imaging agents, including macromolecules which respond to environmental stimuli. He is the Theme Leader of Imaging Technologies in the COE CBNS.

Title of presentation: Recent advances in 19F MRI agents for detection of diseased tissue and cell tracking

 



 

 

 

 

John McGhee

 

Angus Johnston 

 

 mr-adesanya.jpg

 

 

 

ch.png

 

 

 

 

John Marshall

 

Nicola Rogers

thurecht.jpeg

 

aw.jpg